Hashem Mubarak
Cardiovascular Disease · Panama City, FLNPI 1306867502
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 116 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 22 manufacturers, the largest accounting for just 10.6% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $768 and has fallen 98.1% since, to $14 in 2024. That places this record below the midpoint for cardiovascular disease clinicians in FL, where the typical reported total is $2,774.
Across 116 payments — averaging $18.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$225
- Amarin Pharma, Inc.$186
- Amgen$185
- Novartis$179
- Johnson & Johnson$176
- Esperion Therapeutics, Inc.$157
- plus $1K from 16 others
What the payments were for
- Food & beverage$2,111100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 11 | $225 |
| Amarin Pharma, Inc. | 10 | $186 |
| Amgen | 11 | $185 |
| Novartis | 13 | $179 |
| Johnson & Johnson | 12 | $176 |
| Esperion Therapeutics, Inc. | 4 | $157 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 5 | $131 |
| Pfizer | 8 | $129 |
| E.r. Squibb & Sons, L.L.C. | 7 | $104 |
| Bayer | 5 | $88 |
| Chiesi USA, Inc. | 4 | $68 |
| Alnylam Pharmaceuticals Inc. | 3 | $62 |
| Boehringer Ingelheim | 3 | $60 |
| Medtronic(2 entities) | 3 | $55 |
| Abiomed | 2 | $55 |
| Merck | 4 | $54 |
| Sanofi-aventis U.S. LLC | 3 | $50 |
| Boston Scientific | 2 | $50 |
| Astellas Pharma US Inc | 2 | $36 |
| Actelion Pharmaceuticals US, Inc. | 2 | $35 |
| Cardiovascular Systems Inc. | 1 | $14 |
| Daiichi Sankyo Inc. | 1 | $13 |
How this compares
$2,111 in reported general payments places this provider in the 40th percentile of 1,740 cardiovascular disease providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Furosemide | 14 | $106 |
Paid to pharmacies, not to this prescriber.
Other cardiovascular disease in Panama City
- Kevin MakatiLutz$1.6M
- Hiram BezerraTampa$698K
- William OneillNaples$637K
- Theodore FeldmanMiami$637K
- John Gerald CantoLakeland$588K
- Alan MillerJacksonville$547K
- Seth BaumBoca Raton$517K
- Elliott EliasMiami$497K
- Vijay HaryaniVero Beach$413K
- Neel PatelMaitland$392K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.